Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D1HS
|
||||
| Former ID |
DNC000833
|
||||
| Drug Name |
Ki23819
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Target and Pathway | |||||
| Target(s) | FL cytokine receptor | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Hematopoietic cell lineage | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancer | |||||
| References | |||||
| REF 1 | Mol Cancer Ther. 2004 Dec;3(12):1639-49.KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. | ||||
| REF 2 | Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia. 2005 Jun;19(6):930-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.